BACKGROUND: Premature neuronal cell death is a feature of numerous central nervous system and eye diseases, including glaucoma. Neurons (including retinal ganglion cells, RGCs) are protected by several neurotrophic factors, among those the IL-6 family of cytokines. Lately, a novel member of the IL-6 family of cytokines has been identified and cloned. This cytokine is known as novel neurotrophin-1/B-cell-stimulating factor-3 (NNT-1/BSF-3) or cardiotrophin-like cytokine (CLC). It shows neurotrophic as well as B-cell stimulatory effects. METHODS: In this study, the neuroprotective properties of CLC on RGC loss in vivo were investigated. RESULTS: CLC significantly protected RGCs from degeneration in both chosen models of retinal neuronal damage: optic nerve crush (P<0.01) and N-methyl-D-aspartate (NMDA) injection (P<0.001). CONCLUSIONS: CLC shows neuroprotective effects on RGCs in vivo and might be a treatment option for chronic neurodegenerative eye diseases such as glaucoma. Clinical feasibility for the substance requires further investigation since the immunomodulatory and possible adverse effects have not yet been thoroughly characterized.
BACKGROUND:Premature neuronal cell death is a feature of numerous central nervous system and eye diseases, including glaucoma. Neurons (including retinal ganglion cells, RGCs) are protected by several neurotrophic factors, among those the IL-6 family of cytokines. Lately, a novel member of the IL-6 family of cytokines has been identified and cloned. This cytokine is known as novel neurotrophin-1/B-cell-stimulating factor-3 (NNT-1/BSF-3) or cardiotrophin-like cytokine (CLC). It shows neurotrophic as well as B-cell stimulatory effects. METHODS: In this study, the neuroprotective properties of CLC on RGC loss in vivo were investigated. RESULTS:CLC significantly protected RGCs from degeneration in both chosen models of retinal neuronal damage: optic nerve crush (P<0.01) and N-methyl-D-aspartate (NMDA) injection (P<0.001). CONCLUSIONS:CLC shows neuroprotective effects on RGCs in vivo and might be a treatment option for chronic neurodegenerative eye diseases such as glaucoma. Clinical feasibility for the substance requires further investigation since the immunomodulatory and possible adverse effects have not yet been thoroughly characterized.
Authors: E Lelièvre; H Plun-Favreau; S Chevalier; J Froger; C Guillet; G C Elson; J F Gauchat; H Gascan Journal: J Biol Chem Date: 2001-04-06 Impact factor: 5.157
Authors: C Lütticken; U M Wegenka; J Yuan; J Buschmann; C Schindler; A Ziemiecki; A G Harpur; A F Wilks; K Yasukawa; T Taga Journal: Science Date: 1994-01-07 Impact factor: 47.728
Authors: S Thaler; C Haritoglou; F Schuettauf; T Choragiewicz; C A May; F Gekeler; M D Fischer; H Langhals; A Schatz Journal: Eye (Lond) Date: 2014-12-19 Impact factor: 3.775
Authors: Elaine C Johnson; Thomas A Doser; William O Cepurna; Jennifer A Dyck; Lijun Jia; Ying Guo; Wendi S Lambert; John C Morrison Journal: Invest Ophthalmol Vis Sci Date: 2011-01-25 Impact factor: 4.799
Authors: Nancy Lee; Rachel P Spearry; Kendra M Leahy; Rachel Robitz; Dennis S Trinh; Carter O Mason; Rebekah J Zurbrugg; Myra K Batt; Richard J Paul; A John Maclennan Journal: J Comp Neurol Date: 2013-09-01 Impact factor: 3.215
Authors: Sebastian Thaler; Tomasz J Choragiewicz; Robert Rejdak; Michal Fiedorowicz; Waldemar A Turski; Maria Tulidowicz-Bielak; Eberhart Zrenner; Frank Schuettauf; Tomasz Zarnowski Journal: Graefes Arch Clin Exp Ophthalmol Date: 2010-06-08 Impact factor: 3.117